About octagam®
What is octagam®?
Octagam® is a liquid, ready to use intravenous immunoglobulin (IVIg) originally launched in 1995 as the first S/D (solvent/detergent) treated immunoglobulin from Octapharma. Today, octagam® is available in two optimised concentrations, produced using a reliable formulation and robust manufacturing process, resulting in a well tolerated immunoglobulin therapy which is available in more than 80 countries worldwide.1-7
octagam®5%
Since 1995, octagam® has been helping to improve the lives of patients with immune disorders.1,2
A ready-to-use liquid IVIg with convenient room temperature storage.3
octagam®10%
The 10% formulation and well tolerated higher maximum infusion rate, can provide additional convenience.4,5
The same tried and trusted formulation.4
:quality(80))
Trusted in numerous indications3,4
The efficacy and tolerability of octagam® across multiple indications has been demonstrated through numerous clinical studies.1-9
Quality and safety are maintained through the robust manufacturing process.3,4
:quality(80))
Manufacturing
Manufacturing that delivers quality
Octagam® is manufactured to preserve the integrity of IgG and has a distribution of IgG subclasses like in a normal healthy population.3,4,10
Convenient dosing
Octagam® offers tailored immunoglobulin therapy with various vial sizes, two concentrations, and easy handling.3,4
:quality(80))
Join the Octapharma Science Hub
Visit the Octapharma Science Hub to explore in-depth study results and gain insights from expert lectures.
:quality(80))
References
Frenzel W, et al. Tolerability and safety of octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials. Int J Clin Pharmacol Ther. 2016;54(11):847-855.
Debes A, et al. Tolerability and safety of the intravenous immunoglobulin octagam®: a 10-year prospective observational study. Pharmacoepidemiol Drug Saf. 2007;16(9):1038-1047.
Octagam®5%. Summary of Product Characteristics. July 2024.
Octagam®10%. Summary of Product Characteristics. July 2024.
Robak et al. Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam®10%) in patients with immune thrombocytopenia. Hematology. 2010; 15 (5): 351-359.
Ochs HD et al. octagam®5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol. 2004; 24(3): 309-314.
Wietek S et al. Tolerability and safety of the intravenous immunoglobulin octagam®10% in patients with immune thrombocytopenia: A post-authorisation safety analysis of two non-interventional phase IV trials. Hematology. 2018; 23: 242-7.
Aggarwal R. et al. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med. 2022; 6;387(14):1264-1278.
Aggarwal R. et al. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther. 2024; 17;26(1):27.
European Medicines Agency. Guideline on plasma-dervied medicinal products. EMA/CHMP/BWP/706271/2010. 2011.
This is an international website for octagam® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
If you wish to contact Octapharma please use the contact form on our corporate website www.octapharma.com.
